These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 31879973)
1. An economic analysis of different treatments for bleeding in patients with acquired haemophilia. Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973 [TBL] [Abstract][Full Text] [Related]
2. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model. Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154 [TBL] [Abstract][Full Text] [Related]
3. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. You CW; Lee SY; Park SK Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800 [TBL] [Abstract][Full Text] [Related]
4. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100 [TBL] [Abstract][Full Text] [Related]
6. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214 [TBL] [Abstract][Full Text] [Related]
7. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Hay JW; Zhou ZY Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802 [TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427 [TBL] [Abstract][Full Text] [Related]
9. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. Hay JW; Zhou ZY J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366 [TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Lyseng-Williamson KA; Plosker GL Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Iorio A; Matino D; D'Amico R; Makris M Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076 [TBL] [Abstract][Full Text] [Related]
12. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic. Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico. Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158 [TBL] [Abstract][Full Text] [Related]
14. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)]. Szmurło D; Deryło Ł; Ryś P; Władysiuk M Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998 [TBL] [Abstract][Full Text] [Related]
15. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Hay JW; Chaugule SC; Young G Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765 [TBL] [Abstract][Full Text] [Related]
16. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study. Mingot-Castellano ME; García-Candel F; Benítez-Hidalgo O; Marco A; Méndez Navarro GA; Pérez-Montes R; García Donas G; Canaro M; Paloma MJ; Asenjo B; Calle-Gordo VM; González NP; Rodríguez González R; Caparrón-Miranda IS; Quintana París L; Herrero S; Nuñez R Eur J Haematol; 2022 Dec; 109(6):686-695. PubMed ID: 36029160 [TBL] [Abstract][Full Text] [Related]
17. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Knight C; Danø AM; Kennedy-Martin T Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191 [TBL] [Abstract][Full Text] [Related]
18. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927 [TBL] [Abstract][Full Text] [Related]
19. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Putnam KG; Bohn RL; Ewenstein BM; Winkelmayer WC; Avorn J Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272 [TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Matino D; Makris M; Dwan K; D'Amico R; Iorio A Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]